

UNITED STATES PATENT AND TRADEMARK OFFICE

ge 1012

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. BOX 1450 Alexandria, Vuginia 22313-1450

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/816,688

03/22/2001

Katherine A. High

018743-0278737

Robert Bedgood Pillsbury Winthrop LLP 101 W Broadway Suite 1800 San Diego, CA 92101



CONFIRMATION NO. 5212
FORMALITIES LETTER
OC000000013092874

Date Mailed: 06/28/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR §§ 1.821-1.825. The application must be in sequence compliance before examination on the merits.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR § 1.821(g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. In no case may an applicant extend the period for response beyond the six-month statutory period. Direct the response to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

See the attachment.

Applicant Must Provide as part of the response:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

AUG 0 2 2004 Special No.:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant: HIGH, Katherine, et al.

rial No.: 09/816,688

Filed:

March 22, 2001

For:

MODIFIED BLOOD CLOTTING

FACTORS AND METHODS OF

USE

Certificate of Mailing Under 37 C.F.R. §1.8

I hereby certify that this correspondence along with any paper referred to as being attached is being mailed to Addressee by service of the United States Postal Service First Class Mail, postage prepaid, addressed to the United States Patent and Trademark Office,

P.O. Box 1450, Alexandria, VA 22313

Sachiko Y. Snedden

Date: 7-28-04

TRANSMITTAL LETTER

United States Patent and Trademark Office Attn: MAIL STOP SEQUENCE LISTING P.O. Box 1450 Alexandria, VA 22313

Transmitted herewith in the above-identified application are the following documents:

- 1. Copy of Notice to Comply;
- 2. Amendment and Response to Notice to Comply;
- 3. Statement Under 37 CFR §1.821(f) and (g);
- 4. Sequence Listing in computer readable format and hardcopy format; and
- 5. Postcard.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Reg. No. 43,488

Date:

By:

11682 El Camino Real, Suite 200

San Diego, CA 92130

Tel. No.: (858) 509-4065 Fax No.: (858) 509-4010